Company Filing History:
2 out of 153 
1 out of 2 
1 out of 23 Years Active: 2018-2023
Title: Zuxing Weng: Innovator in Hepatitis B Detection
Introduction
Zuxing Weng is a notable inventor based in Xiamen, China. He has made significant contributions to the field of medical diagnostics, particularly in the detection of hepatitis B. With a total of two patents to his name, Weng's work focuses on innovative methods for monitoring and controlling chronic hepatitis B.
Latest Patents
Weng's latest patents include a kit and method for quantitative detection of HBsAg. This kit is designed for the quantitative detection of HBsAg in samples, utilizing a first antibody that specifically binds to HBsAg. The reagent composition in the kit includes tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and urea. Another significant patent is the anti-HBc quantitative detection method, which is instrumental in monitoring disease progression in chronic hepatitis B patients. This method allows for the quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), aiding in predicting therapeutic effects and guiding treatment decisions for patients undergoing therapy.
Career Highlights
Weng has worked with esteemed institutions such as Xiamen University and Xiamen Innodx Biotech Co., Ltd. His experience in these organizations has contributed to his expertise in the field of hepatitis B diagnostics.
Collaborations
Weng has collaborated with notable colleagues, including Liuwei Song and Feihai Xu. These partnerships have further enhanced his research and development efforts in medical diagnostics.
Conclusion
Zuxing Weng's innovative work in hepatitis B detection showcases his commitment to improving patient outcomes through advanced diagnostic methods. His contributions are vital in the ongoing fight against chronic hepatitis B.